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Abstract
Since	the	second	half	of	the	20th	century	the	incidence	of	tuberculosis	has	been	declining	in	Poland.	Despite	this,	current	epidemi-
ological	data	still	support	the	need	for	the	continued	mass	BCG	vaccination	in	Poland	in	the	near	future.	Apart	from	the	protection	
against	severe	hematogenous	forms	of	tuberculosis,	vaccination	lowers	the	risk	of	infection	with	Mycobacterium tuberculosis.	
Primary	and	acquired	immunodeficiency,	including	immunity	disorders	associated	with	an	ongoing	treatment,	are	contraindica-
tions	to	BCG	vaccination.	The	most	common	adverse	effects	following	BCG	vaccination	are	reactions	at	the	site	of	injection	and	
in	regional	lymph	nodes,	which	usually	does	not	require	treatment.
Methods	of	tuberculosis	prevention,	particularly	recommended	in	low-incidence	countries,	include:	diagnostic	investigations	of	
patients	who	had	contacts	with	pulmonary	tuberculosis	as	well	as	an	active	detection	and	treatment	of	latent	Mycobacterium 
tuberculosis	infection.	Latent	tuberculosis	infection	can	be	identified	on	the	basis	of	positive	results	of	the	tuberculin	skin	test	or	
interferon-gamma	release	assays	after	the	active	disease	has	been	ruled	out.	This	condition	does	require	prophylactic	treatment.
Key words:	BCG	vaccination,	tuberculosis	contact	investigation,	latent	tuberculosis	infection
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The recommendations were developed on be-
half of the Polish Society of Pediatric Pulmonology 
and National Consultant of Pediatric Pulmonology 
by the group of experts — TB Team. 
The chairperson of the Team: Zbigniew 
Doniec — National Consultant of Pediatric Pul-
monology. 
The Team coordinator: Marek Popielarz
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List of abbreviations:
AAP — American Academy of Pediatrics
AFB — acid fast bacilli
BCG — baciilus Calmette-Guerin
CDC — Centers for Disease Control  
and Prevention
EMB — ethambutol
HIV — human immunodeficiency virus
IGRA — interferon gamma release assay
INH — isoniazid
IUATLD — International Union Against 
Tuberculosis and Lung Disease
LTBI — latent tuberculosis infection
PZA — pyrazinamide
RMP — rifampicin
TBnet — Tuberculosis Network
TNF-alpha — tumor necrosis factor alpha
VAE — vaccine adverse event
WHO — World Health Organization
Since the 1950s, the incidence of tuberculosis 
has been systematically declining in Poland [1]. 
In 2010, Poland has become a low-incidence 
country, where the role of tuberculosis prevention 
is particularly emphasized [2].
Basic tuberculosis prevention methods 
include the following:
• BCG vaccination;
• detection of latent tuberculosis infection 
(prophylactic and preventive treatment in 
risk groups);
• active tuberculosis detection in risk groups;
• isolation and immediate treatment of infec-
tious patients [2].
This article presents current guidelines con-
cerning BCG vaccination, tuberculosis contact 
investigation as well as the diagnostic workup and 
preventive treatment of latent tuberculosis infection.
BCG vaccination
The BCG vaccine contains the attenuated live 
strain of bovine tuberculosis bacillus (M. bovis). 
The vaccine has been named after its creators: 
Albert Calmette and Camille Guerin: M. bovis BCG 
(Bacillus Calmette- Guerin). Its implementation in 
the 1920s significantly decreased the incidence 
of severe hematogenous forms of tuberculosis 
(miliary tuberculosis and tuberculous meningitis) 
among infants and young children and reduced 
mortality associated with this disease [2, 3]. Cur-
rent data indicate that BCG vaccination also lowers 
the risk of infection with Mycobacterium tubercu-
losis by approximately 19% and decreases the risk 
of progression to active tuberculosis by 71% [4–7].
According to the recommendations of the 
International Union Against Tuberculosis and 
Lung Diseases (IUATLD) [8], mass BCG vaccina-
tion is recommended in countries with sputum 
smear-positive pulmonary tuberculosis inci-
dence equal to or greater than 5/100,000 in the 
past 3 years. Despite a continuously improving 
situation in Poland, this value reached 7.3–
7.1–6.8/100,000/year in the years 2014–2016, 
respectively [1].
As all other compulsory vaccination pro-
grams, BCG vaccination is mandatory, and any 
refusal should be reported in writing to the local 
public health inspector [9].
Contraindications to BCG vaccination (apart 
from those generally acknowledged for all vac-
cines) include the following [10, 11]:
• body mass ≤ 2,000 g,
• congenital impairment of cell-mediated im-
munity or its suspicion,
• impairment of cell-mediated immunity in the 
family until their exclusion in the child,
• HIV infection (children of HIV-positive moth-
ers can be vaccinated after HIV infection in 
the child has been ruled out),
• immunosuppression (e.g. steroid therapy, 
cytostatic drugs, treatment with TNF-alpha 
antagonists, radiotherapy),
• immunosuppressive treatment of the mother 
in the third trimester of gestation (vaccina-
tion should be postponed; in the case of treat-
ment with TNF-alpha antagonists in the third 
trimester of pregnancy, the concentrations of 
the above mentioned drugs in the blood of 
infants have been detected up to the 6th, or 
even 12th month of life) [12, 13],
• leukemia, lymphoma, disseminated cancer,
• generalized skin infections (until their re-
gression),
• pregnancy,
• history of tuberculosis or infection with My-
cobacterium tuberculosis,
• ongoing anti-tuberculosis treatment (e.g. 
preventive).
BCG vaccination program
I. General principles
1. According to the WHO recommendations 
concerning countries where the epidemiolog-
ical situation requires immunization, a BCG 
vaccine should be administered once in a 
lifetime, as soon as possible after birth [14].
2. According to the Polish preventive vaccina-
tion program, the BCG vaccine is obligatory 
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up to 15 years of age if the child has not been 
vaccinated after birth [15].
3. As the lack of revaccination efficacy has 
been documented, it is no longer performed 
[16].
II. Detailed principles
1. Vaccination of neonates
—  a vaccine can be administered after col-
lecting the family history of congenital 
immunodeficiency.
—  in children of HIV-positive mothers, vac-
cination should be postponed until the 
infection in the child has been ruled out.
—  a vaccine is administered following the 
consent and in the presence of a parent 
or legal guardian.
2. Vaccination after the neonatal period
The procedures to be performed before vac-
cination:
—  collect the family history of congenital 
immunodeficiency;
—  basing on the history and physical ex-
amination, determine whether the child 
manifests typical signs of immunodefi-
ciency (e.g. failure to thrive, recurring 
severe infections, chronic diarrhea, re-
current bacterial or fungal infections 
of the skin and mucous membranes, 
abscesses in the skin or organs) [17];
—  basing on the history, estimate the risk of 
M. tuberculosis infection and determine 
whether a child has been or is in close 
contact with a tuberculosis patient or 
has a close contact with a person with 
chronic cough that has not been diag-
nosed;
—  if the child has been or is in contact with 
an infected individual, tests have to be 
ordered in accordance with diagnostic 
principles presented below regarding 
the children who have come into contact 
with a tuberculosis patient;
—  in the case of chronic coughing of an 
undiagnosed individual in the house-
hold settings, a plain chest radiograph 
for this person has to be ordered. If 
the results do not indicate tuberculo-
sis, the child can be vaccinated. If the 
diagnosis of the coughing person is 
impossible, test the child with the TST 
and/or IGRA;
 —  when in doubt as to the risk of exposure 
to M. tuberculosis (e.g. in the school 
settings), inform the parents and the 
patient about a possibility to perform 
diagnostic tests (TST and/or IGRA) be-
fore BCG vaccination and about the risk 
of a local accelerated reaction in persons 
with tuberculosis infection [18];
—  vaccinate after obtaining consent from 
the parent or de facto carer;
—  up to the age of 6 years, vaccinate in the 
presence of the parent, legal guardian or 
de facto carer;
The diagnostic procedures before BCG vac-
cination of children suspected of having had 
a contact with a person with pulmonary tuber-
culosis are not dictated by vaccination safety but 
by epidemiological reasons, and their aim is to 
detect infected individuals early. There are no 
data about an increased risk of severe vaccination 
reactions after administering the vaccine to a pa-
tient infected with M. tuberculosis. However, the 
risk of the Koch’s phenomenon, i.e. accelerated 
local reaction, is increased [18].
3. Immunization of children and adolescents 
without vaccination records (e.g. immigrants, 
refugees)
If vaccination records are not available, 
children up to the age of 15 should undergo BCG 
vaccination after a prior exclusion of infection, in 
accordance with the principles explained above.
Normal local reaction after BCG 
vaccination
A natural, local reaction after BCG vacci-
nation involves redness appearing 2–3 weeks 
after the injection. Several weeks later, a nodule 
evolving to a pustule develops. It then ruptures 
to form a slight ulceration, and then crusts. The 
crust usually falls off after 8–10 weeks, leaving 
a slight scar measuring 6–8 mm in diameter [10]. 
The diameter of the pustule and ulceration should 
not exceed 10 mm in children vaccinated in the 
first year of life, and 20 mm in children vaccinated 
at an older age. A greater ulceration is considered 
a vaccine adverse event (VAE). The total healing 
time does not usually exceed 3 months [10]. The 
skin reaction at the site of BCG injection is usually 
accompanied by slightly enlarged (to 15 mm in 
diameter) lymph nodes (axillary, supraclavicular, 
subclavicular) [10].
Adverse events after BCG vaccination
The risk of VAEs is associated with the dosage, 
substrain (reactogenicity) of bacteria included in 
the vaccine and the manner of administration [5]. 
Differences between individual substrains have 
appeared as a result of passages in different labo-
ratory settings over many years [19]. The Danish 
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and French Pasteur substrains induce more ad-
verse effects than the Tokyo and Glaxo substrains 
or the Brazilian Moreau substrain commonly used 
in Poland [5].
VAEs after BCG vaccine include local and 
nodal reactions (usually mild) as well as distant 
and generalized effects. The most severe VAEs 
(distant reactions and disseminated M. bovis 
infection after BCG vaccination) mainly develop 
in severely immunocompromised individuals.
Management of VAEs after BCG vaccination:
1. Local reactions
• Ulcerations and abscesses > 10 mm in 
diameter (in infants vaccinated in the first 
year of life) or > 20 mm (in children vacci-
nated later) are usually of self-limiting nature 
[5, 20]. Observation and protection against 
superinfection are recommended.
• A local accelerated reaction (Koch’s pheno-
menon) is an inflammatory reaction (redness, 
pustule and ulceration), which develops 
within 6 days after vaccination, usually af-
ter 24–48 hours. It occurs in persons with a 
tuberculosis infection [5], which necessitates 
a diagnostic process to confirm the infection 
(IGRA).
• A keloid, a raised nodular lesion of an ir-
regular shape, at the BCG injection site is 
associated with pathological healing of the 
vaccination site. A consultation with a der-
matologist or plastic surgeon is recommend-
ed [21].
2. Nodal reactions: enlarged (> 15 mm) regional 
lymph nodes (axillary, supraclavicular, sub-
clavicular), on the side of vaccination.
The symptoms can develop within a week to 
even a dozen weeks after vaccination. In lymph-
adenopathy without accompanying purulent re-
actions, observation is sufficient. In suppurative 
lymphadenitis, the following are recommended:
— slight reactions: observation only,
— signs suggesting a fistula (fluctuation of the 
purulent content, skin thinning over the 
affected node): aspiration puncture and 
collection of the material for bacteriological 
examination for the concomitant infection. 
The puncture shortens the duration of the 
reaction, lowers the risk of spontaneous 
perforation and formation of a disfiguring 
scar [22–24].
Lymph node removal is not recommended 
as it is the last resort in persisting purulent in-
flammation.
3. Distant reactions
Distant reactions include:
• skin changes (ulcerating, lichenoid, nodular) 
beyond the injection site, erythema nodo-
sum,
• iritis, conjunctivitis, optic neuritis,
• osteomyelitis [5].
Osteomyelitis
In Poland, it usually develops in individu-
als with cell-mediated immunity impairment. 
However, this complication is also observed in 
immunocompetent individuals [25] in countries 
where more reactogenic BCG substrains (Pasteur 
and Danish) are used [5].
It manifests as a bone defect, soft tissue ede-
ma, pain, restricted mobility and sparing of the 
affected area [25].
If this complication develops, the patient must 
be diagnosed with immunodeficiency (cell-mediat-
ed immunity disorders, severe immunodeficiency, 
HIV infection), and the etiology of infection must 
be confirmed (bacteriological tests for M. bovis 
BCG in the referential tuberculosis laboratory). The 
treatment consists in combined anti-tuberculosis 
therapy without pyrazinamide (PZA) as M. bovis 
BCG is naturally resistant to this drug. Certain 
cases do require surgical intervention.
If multiple changes are observed, the patient 
should be diagnosed with systemic BCG dissem-
ination.
Disseminated and systemic tuberculosis 
(BCG-itis) develops very rarely, usually in persons 
with a more severe impairment of cell-mediated 
immunity [26–28].
BCG-itis is manifested by general signs: fever 
or subfebrile temperature, failure to thrive, and 
distant tuberculosis changes beyond the injection 
site (in the skin, lymph nodes, lungs, liver, spleen, 
bones and soft tissues) [28]. When BCG-itis is 
suspected or there are distant reactions after 
BCG vaccination, the patient requires urgent di-
agnosis and treatment in a specialist center with 
diagnostic facilities enabling the identification 
of immunodeficiency (cell-mediated immunity 
deficits, severe complex immunodeficiency) and 
confirmation of the etiology of infection. The 
treatment involves first-line antituberculous 
agents excluding PZA: isoniazid (INH), rifampicin 
(RMP) and ethambutol (EMB). When the suspi-
cion of BCG-itis is justified, treatment should be 
implemented instantaneously before bacteriolog-
ical confirmation arrives. The prognosis is grave.
General guidelines for VAEs after BCG vaccination
Obligatory procedures to be performed in all 
children with a VAE after BCG vaccination:
Teresa Bielecka et al., Tuberculosis prevention
153www.journals.viamedica.pl
• collect the family history of immunodefi-
ciency,
• collect the history concerning the occur-
rence of the following symptoms: subfebrile 
temperature, appetite disorders, failure to 
thrive, apathy
• conduct a careful physical examination with 
particular attention paid to: skin reactions, 
peripheral lymph nodes, percussion signs 
over the lung fields as well as the size of the 
liver and spleen,
• assess complete blood count (with the em-
phasis on the absolute lymphocyte count),
• report VAEs to the local public health inspector.
Local and nodal reactions after BCG vacci-
nation are not contraindications to the continu-
ation of the remaining immunization programs 
in accordance with the Preventive Vaccination 
Program.
Diagnostic workup for latent tuberculosis 
infection (LTBI) 
Latent tuberculosis infection can be identi-
fied basing on positive immunological tests: the 
tuberculin skin test and/or IGRA in the absence 
of clinical and radiological signs of tuberculosis.
As stated in the WHO guidelines from 2015, 
systematic screening for and proper treatment of 
LTBI in countries with annual incidence of tuber-
culosis < 100/100,000 and with a good economic 
status should be conducted in:
• HIV-infected individuals,
• children and adults who have come into 
contact with a person with pulmonary tu-
berculosis,
• patients with planned treatment with 
TNF-alpha antagonists,
• organ or bone marrow transplant recipients,
• patients on dialysis,
• patients with silicosis.
Screening for LTBI should also be considered 
in:
• immigrants or refugees from countries with 
widespread tuberculosis,
• drug addicts,
• the homeless,
• prisoners,
• health care personnel [29].
The quoted WHO guidelines do not indicate 
the need for LTBI screening before the implemen-
tation of long-term immunosuppressive treat-
ment (except for organ and bone marrow trans-
plant recipients and candidates for TNF-alpha 
antagonist therapy). However, the opinion of the 
Centers for Disease Control and Prevention (CDC), 
published in 2014, and of the American Acade-
my of Pediatrics (Red Book 2015) are different. 
Their experts believe that long-term steroid or 
immunosuppressive therapy is an indication for 
LTBI tests [30, 31].
Some authors suggest that both steroid ther-
apy and other immunosuppressants increase the 
risk of developing tuberculosis, but to a lower 
degree than TNF-alpha antagonists [32, 33].
It therefore seems justified to screen for LTBI 
before the implementation of any prolonged 
immunosuppressive treatment in children and 
especially in the following situations:
• in patients at a high risk of tuberculosis 
infection (positive family history of tuber-
culosis, origin from a country with high 
incidence of tuberculosis),
• if treatment with TNF-alpha antagonists is 
planned as the next step of therapy (this 
is because the TST and IGRA do not yield 
reliable outcomes after implementation of 
steroids or other immunomodulatory drugs).
Before performing diagnostic tests for latent 
M. tuberculosis infection, typical signs of active 
tuberculosis must be ruled out (persisting cough, 
subfebrile temperature, weight loss or failure to 
thrive, night sweats, weakness, chest pain, he-
moptysis). When active tuberculosis is suspected, 
the diagnostic process should be extended: a plain 
chest radiography and bacteriological tests for 
tuberculosis should be ordered.
In order to identify M. tuberculosis infection 
in accordance with the WHO guidelines, the tu-
berculin skin test or IGRA have to be performed.
According to the guidelines of the Tubercu-
losis Network (TBnet), both tests should be used 
simultaneously in children before the transplan-
tation of solid organs and bone marrow and prior 
to treatment with TNF-alpha antagonists [34, 35].
Furthermore, due to a higher diagnostic 
sensitivity with both tests, their simultaneous ap-
plication should be considered in the remaining 
patients with a high risk of developing tubercu-
losis (Table 1).
In children with a low risk of TB disease, TST 
or IGRA may be used. 
When any of these tests are positive, a plain 
chest radiography should be performed. The 
presence of abnormalities compatible with tu-
berculosis forces an extended diagnostic process 
(including bacteriological tests for tuberculosis). 
Positive TST or IGRA (after ruling out active 
tuberculosis) is an indication for LTBI diagnosis 
and implementation of treatment. The aim of 
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LTBI treatment is to lower the risk of developing 
active tuberculosis. The following LTBI treatment 
regimens are proposed by WHO:
• INH once daily for 6 to 9 months,
• INH + RMP once daily for 3–4 months,
• RMP once daily for 3–4 months,
• INH + Rifapentine (not yet registered in 
Poland) once a week for 3 months.
There are no studies that would show the 
superiority of any of the 6- or 9-month INH thera-
py; WHO indicates equivalence of both regimens. 
The American Academy of Pediatrics suggests 
9 months [31], while the 6-month regimen is 
recommended in Poland.
The dosage in LTBI is consistent with that 
used in the treatment of active tuberculosis:
• INH in children: 10 mg/kg (7–15 mg/kg), in 
adults: 5 mg/kg (a maximum daily dose 300 mg),
• RMP in children: 10 mg/kg (10–20 mg/kg), 
in adults: 10 mg/kg (a maximum daily dose 
600 mg) [14, 29].
It must be remembered that only INH is regis-
tered for preventive treatment in Poland. Parental 
consent must be acquired for off-label use of RMP.
Prior to the initiation of treatment, baseline 
values of transaminases and bilirubin should be 
determined in:
• patients with an earlier or current liver disease,
• patients abusing alcohol,
• HIV-infected individuals,
• pregnant women or in the first 3 months 
after childbirth.
If baseline transaminase values are slightly 
increased, they must be systematically monitored 
during the treatment.
 The remaining patients treated for LTBI 
should be regularly examined by a physician 
(clinical assessment, motivation to continue treat-
ment, adverse effects monitoring). Patients and 
their parents should be familiar with potential 
adverse effects in order to report to the doctor 
immediately if they develop. The most common 
adverse effects are as follows: loss of appetite, 
nausea, vomiting, abdominal pain, fatigue, weak-
ness, dark urine, pale stool and jaundice. If these 
symptoms develop and medical consultation is 
not possible, the treatment should be stopped. 
Tuberculosis contact investigation
In accordance with the Act of 5 December 
2008 on Prevention and Treatment of Infections 
and Infectious Diseases in Humans, individuals 
who come into contact with a tuberculosis patient 
should be under epidemiological surveillance, 
should undergo clinical examination and diag-
nostic tests or if needed, a preventive pharmaco-
logical treatment [9].
Contact with tuberculosis patient (necessitat-
ing diagnostic measures) is defined as:
—  staying in one room with a sputum smear-pos-
itive individual (acid fast bacilli+, AFB+) for 
a total of 8 hours for up to 3 months before 
diagnosis;
—  staying with a sputum smear-negative (AFB-) 
but sputum culture-positive individual for 
cumulative 40 hours for up to a month before 
diagnosis;
—  a brief intensive face-to-face contact (e.g. 
during a laryngological examination or dental 
treatment) with a patient with pulmonary 
tuberculosis [33].
NOTE: The presence of a cavity on chest 
radiography or a cough increases the degree of 
infectiousness.
A tuberculosis patient stops being infec-
tious approximately 2 weeks after the treatment 
implementation (when bacterial sensitivity to 
the treatment is presumed or confirmed, and the 
clinical improvement is noted).
Diagnostic tests should be conducted in 
individuals exposed to an index case of bacte-
riologically confirmed pulmonary tuberculosis 
(with positive sputum cultures or smears when 
the molecular tests have revealed that the bacte-
ria do belong to the M. tuberculosis complex). In 
the case of individuals with a very high risk of 
tuberculosis (e.g. severely immunocompromised 
patients, neonates) coming into contact with a 
patient with tuberculosis which has not been 
Table 1. Factors that increase the risk of disease progres-
sion after infection [36]
Age	<	5	years	
HIV	infection	or	other	congenital	or	acquired	immunodeficiency
Disorders	of	the	IFN-g–Il-12	axis
Diabetes
Prolonged	steroid	therapy	(>	4	weeks,	prednisone	1	mg/kg	per	
day	or	>	15	mg	per	day)
Immunosuppressive	treatment,	treatment	with	TNF-a	antago-
nists
Hematologic	diseases	or	diseases	of	the	reticuloendothelial	
system
Severe	chronic	renal	failure
Chronic	absorption	disorders
Smoking
Underweight
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Table 2. Time and manner of tuberculosis contact investigation
Time of examination
Urgent: < 1 week after diagnosis or as soon as 
possible
8 weeks after the last contact with 
the index case during the period of 
infectiousness
Children	from	the	close	contact	group1	
at	high	risk	of	tuberculosis2	or	with	clini-
cal	signs	of	tuberculosis
TST,	IGRA	and	chest	radiography TST,	IGRA	and	chest	radiography
The	remaining	children	from	the	close	
contact	group
TST	or	IGRA3 TST	or	IGRA	
Children	from	the	casual	contact	group4	
at	high	risk	of	tuberculosis
TST,	IGRA	and	chest	radiography TST	and	IGRA	
The	remaining	children	from	the	casual	
contact	group
— If	infection	transmission	has	been	
confirmed	in	children	from	the	close	
contact	group:	TST	or	IGRA
Children	from	the	community	contact	
group5
— If	significant6	infection	transmission	has	
been	confirmed	in	children	from	the	ca-
sual	contact	group:	TST	and/or	IGRA
1Close	contact:	household	or	long-term	contact	in	confined	space	or	close	face-to-face	contact,	e.g.	during	medical	procedures	(e.g.	dental	treatment)
2High	risk	of	tuberculosis:	see	Table	1.
3Urgent	examinations	are	indicated	only	when	transmission	has	been	documented	among	children	at	high	risk	of	developing	tuberculosis
4Casual	contact:	frequent	contact	e.g.	frequent	visitors	at	home,	class	mates	or	those	who	spend	free	time	together
5Community	contact	e.g.	at	school	or	sports	club
6Significant	infection	transmission:	when	proved	that	more	than	1	person	has	been	infected	in	casual	contact	group
bacteriologically confirmed, indications to a fur-
ther diagnosis may be considered individually.
According to the European consensus, in the 
case of suspected tuberculosis with a negative 
sputum smear (and when the culture results 
have not yet arrived), the presence of a cavity in 
the chest radiography is an indication to pursue 
the source’s contacts investigation (particularly 
children < 5 years of age or other high-risk indi-
viduals with conditions listed in Table 1).
An overview of organization and timing of 
tuberculosis contact investigations is presented 
in Table 2.
Urgent examinations
Children with an increased risk of developing 
tuberculosis (Table 1) who have come into contact 
with an index case should be examined first as 
soon as possible.
This group should preferably undergo both 
TST and IGRA (if available) as well as a chest ra-
diography. Children with clinical or radiological 
signs suggestive of tuberculosis should undergo 
bacteriological tests.
When conducting TST, the site of tuberculin 
injection must be documented in the patient’s 
records (the first TST should be performed on 
the inner aspect of the left mid-forearm; so-called 
first field).
If TST or IGRA are positive, but there are 
no clinical or radiological signs, LTBI should be 
identified and the prophylactic treatment started.
Indications for a chest radiography in tuber-
culosis contacts are listed in Table 3.
When in doubts about the results of the chest 
radiography (e.g. suspicion of lung hilar lymph 
nodes enlargement), contrast-enhanced computed 
tomography of the chest should be conducted.
When TST and IGRA are negative and there 
are no clinical or radiological signs in children 
with a high risk of developing tuberculosis (< 5 
years of age, HIV-positive, receiving immunosup-
pressive treatment), preventive treatment with 
INH should be initiated.
The remaining children from the close contact 
group may also be optionally tested urgently. This 
is even more justified with confirmed transmission 
Table 3. Indications for chest radiography in tuberculosis 
contacts
Clinical	sings	compatible	with	tuberculosis:
persisting	cough,	night	sweats,	failure	to	thrive,	subfebrile	tem-
perature,	auscultatory	changes	over	the	lung	fields
HIV	infection,	immunodeficiency	either	congenital	or	associated	
with	ongoing	treatment
Age	<	5	years
Positive	TST	or	IGRA
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Table 4. The criteria for interpretation of a positive TST in investigated tuberculosis contacts (according to the European 
consensus)
Risk of tuberculosis 
infection
Factors affecting the risk of tuber-
culosis
Non-BCG-vaccinated or BCG-vac-
cinated in the first year of life
BCG-vaccinated after the first 
year of life
High	(close	contact	
with	a	smear-positive	
tuberculosis	patient)
Immunocompetent ≥	10	mm ≥	15	mm
Immunocompromised
HIV	infection Negative	TST	does	not	exclude	
infection
Negative	TST	does	not	exclude	
infection
Other	factors	of	high	risk	of	develo-
ping	tuberculosis
≥	5	mm ≥	5	mm
Low	(other	contacts	
of	tuberculosis	pa-
tient)
Immunocompetent ≥	15	mm TST	not	recommended
Immunocompromised
HIV	infection Negative	TST	does	not	exclude	
infection
Negative	TST	does	not	exclude	
infection
Other	factors	of	increased	risk	of	
developing	tuberculosis ≥	10	mm ≥	10	mm
among children with a high risk evaluated in the 
first place. Preventive treatment is not applied 
in immunocompetent children > 5 years of age.
Tests after an 8-week window
Eight weeks after the last contact with an 
infectious individual, children previously ex-
amined urgently are re-examined, and all other 
contact children undergo tests.
Children with a high risk of developing 
tuberculosis undergo repeated TST, IGRA and a 
chest radiography.
When conducting a repeated tuberculin skin 
test within a short period of time, one must remem-
ber about changing the site of tuberculin injection 
(the second field: the inner aspect of the right 
mid-forearm) so as to reduce the risk of a booster 
effect, which results in an increased skin reaction. 
If there are radiological abnormalities or clinical 
signs, bacteriological tests should be conducted.
In children > 6 months of age and < 5 years 
of age treated preventively with INH, the treat-
ment can be discontinued once the repeated TST 
and IGRA are negative and there are no clinical/ 
/radiological signs of the disease.
In children < 6 months of age, HIV-infected 
or severely immunosuppressed, the preventive 
treatment with INH should be continued for 
6 months even when TST and IGRA are negative.
TST or IGRA, and optionally also a chest 
radiography, should be conducted in children 
> 5 years of age without additional risk factors of 
tuberculosis. If there are radiological abnormal-
ities or clinical signs, bacteriological tests must 
be ordered.
If TST or IGRA are positive but there are no 
clinical or radiological signs of tuberculosis, LTBI 
should be identified and preventive treatment 
started (according to regimens presented above).
The criteria for interpretation of a positive TST 
in investigated tuberculosis contacts, as provided 
in the European consensus, are shown in Table 4.
As for pulmonary tuberculosis contacts in 
the school settings, screening should start with 
high-risk individuals and those who have had the 
closest and the longest contact with the patient 
(e.g. class mates, so-called “first circle”). If the 
infection transmission is confirmed in the first 
circle, diagnostic tests should also be conducted 
in occasional contacts (“second circle”).
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